![]()
|
Report Date : |
31.12.2008 |
IDENTIFICATION DETAILS
|
Name : |
HIKMA PHARMA SAE |
|
|
|
|
Registered Office : |
2nd
Industrial Zone, Plot No.1, |
|
|
|
|
Country : |
|
|
|
|
|
Financials (as on) : |
31.12.2007 |
|
|
|
|
Year of Establishment : |
1985 |
|
|
|
|
Com. Reg. No.: |
87081 |
|
|
|
|
Legal Form : |
Egyptian Joint Stock Company |
|
|
|
|
Line of Business : |
Manufacture and Export of Pharmaceuticals |
RATING & COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 1,500,000 |
|
|
|
|
Status : |
Good |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
Company Name : HIKMA PHARMA SAE
Country of Origin :
Legal Form : Egyptian Joint Stock Company
Registration Date : 1985
Commercial Registration Number : 87081
Issued Capital : £E 100,000,000
Paid up Capital : £E 20,000,000
Total Workforce : 630
Activities : Manufacture and export of pharmaceuticals
Financial Condition : Good
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 1,500,000
HIKMA PHARMA SAE
Location : 2nd
Industrial Zone, Plot No.1
PO Box : 1913
Town : 6th
of
Country :
Telephone : (20-2) 38331643
/ 38331691 / 38331995 / 38331996 / 38331998 / 38331447
Facsimile : (20-2) 38331791
Subject operates
from a large suite of offices and a factory that are owned and located in the
Industrial Area of the 6th of October City.
Branch Office
(s)
Location Description
·
2 El Messaha Square Rented
office premises
Dokki,
Tel: (20-2)
37490140 / 37490141 / 37490142 / 37490143
Fax: (20-2)
37499253 / 37490144
Name Position
·
Dr. Hassan Shafik Chairman
·
Dr. Nagui Botrous Sales
Manager
·
Wagih Zaki Finance
Manager
·
Dr. Zein El Abedin Mohamed Ibrahim Factory
Manager
Date of Establishment : 1985
Legal Form :
Egyptian Joint Stock
Company
Commercial Reg. No. : 87081
Authorised
Capital : £E 100,000,000
Issued Capital : £E 100,000,000
Paid up Capital :
£E 20,000,000
·
Hikma
Pharmaceuticals Plc
W1S 1HL
United Kingdom
Tel: (44-20) 73992760
Fax: (44-20) 73992761
Activities: Engaged in the manufacture and export of
pharmaceuticals.
Import
Countries:
Operating Trend: Steady
Subject has a workforce
of approximately 630 employees.
Financial
highlights provided by local sources are given below:
Currency: Egyptian
Pounds (£E)
Year
Ending 31/12/06: Year
Ending 31/12/07:
Total Sales £E 84,000,000 £E 102,000,000
Local sources
consider subject’s financial condition to be Good.
The above financial
figures are based on estimations by our local sources.
·
National
Bank of
24,
Tel : (20-2) 3924175
Fax : (20-2) 3924143
·
Export Development
Bank of
4th Industrial
Region, Plot 3/1
6th of
Tel : (20-2) 38330577 / 38330599
Fax : (20-2) 38330570 / 38330551
No complaints
regarding subject’s payments have been reported.
During the course
of this investigation nothing detrimental was uncovered regarding the manner in
which payment obligations are fulfilled. The operating history is clear and the
financial situation is satisfactory. As such we are of the opinion that the subject
is a fair trade risk and the above credit figure is within subject’s financial
means.
FOREIGN EXCHANGE RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.48.50 |
|
|
1 |
Rs.70.02 |
|
Euro |
1 |
Rs.67.95 |
RATING EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)